Morphological and Skeletal Abnormalities Induced by Rolapitant: An Antiemetic Agent

Sohel Solanki 1, Yogesh Yadav 1, Shukturba Dutta 2, Nisha V. Kaul 1, Rashmi Belodu 3, Hareesh RS Kumar 4

1. Department of Anatomy, Santosh Medical College, Santosh University, Delhi NCR, IND 2. Department of Pharmacology, Santosh Medical College, Santosh University, Delhi NCR, IND 3. Department of Microbiology, Dr. N. Y. (Nandakumar Yadav Rao) Tasgaonkar Institute of Medical Science, Raigad, IND 4. Department of Forensic Medicine and Toxicology, Government Medical College and Associated Hospital, Barmer, IND

Corresponding author: Sohel Solanki, sohail.solanki11@gmail.com

Abstract

Introduction
Rolapitant hydrochloride is a highly selective, long-acting antagonist of the neurokinin-1 (NK1RA) receptor with a high level of central nervous system (CNS) penetrance. Clinically, it is given to cancer patients with high and moderate emetogenic chemotherapy to prevent chemotherapy-induced nausea and vomiting (CINV). The facts produced in this research support the interpretation of teratogenic effects like anatomical malformations and abnormal skeletal changes affected by high doses of rolapitant in developed chick embryos, which can be extrapolated to humans due to gaps in the literature regarding the teratogenic potential of rolapitant. As rolapitant is metabolized by the liver and excreted through the kidney by leaving a deep impact on the various systems of the body and due to its high plasma concentration with a half-life of more than 180 hours, the study was conducted to acquire some additional information about its adverse effects over the various body systems. Chick is one of the best animals for embryological laboratory research. For various reasons, it is preferred to research embryology in chicks or domestic hens (Gallus domesticus). Chick eggs are large, readily available all year, easy to incubate, and regulate artificially.

Aim
This study aimed to determine the morphological and skeletal abnormalities due to the effect of rolapitant, an antiemetic agent, in developing White Leghorn (G. domesticus) chicken eggs.

Materials and methods
The experiment used 300 fertilized White Leghorn chicken eggs. The eggs were categorized into five experimental groups (A, B, C, D, and E, each with 30 eggs) and five control groups (a, b, c, d, and e, each with 30 eggs). Rolapitant was administered into the five experimental groups of eggs on incubation day five at various concentrations of 0.00039, 0.0005, 0.00075, 0.001, and 0.00125 mg, respectively, while the control groups received the same volume (0.039, 0.05, 0.075, 0.1, and 0.125 ml, respectively) of normal saline.

Results
At all doses, the mean weight and crown-rump (CR) length of chick embryos were significantly greater in the control group than in the experimental group. The experimental group died at a higher rate than the control group. Additionally, it was found that the mortality due to the rolapitant dosages increases with dose. All groups except group A showed skeletal anomalies such as poor ossification, bent, and displacement, and morphological abnormalities such as yolk sac retraction, hematoma, and scanty feathers were found in experimental groups C, D, and E. This was shown to be more prevalent in the experimental groups and was exacerbated by subsequent rolapitant dosages.

Conclusion
Rolapitant is toxic when taken in large doses and for an extended period. As a result, rolapitant should be taken only when a valid diagnosis has been established and only at the recommended dose, not at a larger dose or for an extended period of time.

Categories: Medical Education, Anatomy
Keywords: weight and crown-rump length, teratogenic effect, antiemetic agent, skeletal abnormalities, morphological abnormalities, chick embryos, rolapitant

How to cite this article
Solanki S, Yadav Y, Dutta S, et al. (August 17, 2022) Morphological and Skeletal Abnormalities Induced by Rolapitant: An Antiemetic Agent. Cureus 14(8): e28097. DOI 10.7759/cureus.28097
was supplemented to 5-hydroxytryptamine receptor antagonist (5-HT3RA) dexamethasone combination in
patients undergoing moderately emetogenic cancer chemotherapy (MEC) or extremely emetogenic cancer
chemotherapy/high emetogenic cancer chemotherapy (HEC). Rolapitant has also been shown to protect
against chemotherapy-induced nausea and vomiting (CINV) throughout the high-risk phase after
chemotherapy, corresponding to the drug’s pharmacokinetics [1].

Rolapitant hydrochloride is a long-acting, extremely selective antagonist of the NK-1 receptor antagonist
(NK-1RA) that significantly penetrates the central nervous system (CNS). In 2015, the Food and Drug
Administration (FDA) authorized rolapitant, a new NK1RA inhibitor, to treat delayed CINV. Its half-life is
180 hours, which is much longer than that of oral aprepitant (9-15 hours). Rolapitant has been licensed to
treat delayed nausea and vomiting induced by emetogenic cancer chemotherapy but is not limited to
extremely emetogenic chemotherapy when combined with additional antiemetic medications [2].

Rolapitant is rapidly absorbed and detectable in plasma after 30 minutes of oral administration; the
maximum plasma concentration (Cmax) is obtained after four hours. The increases in dose-enhanced
rolapitant’s systemic exposure (a four-fold increase from the recommended therapeutic dose of 180 mg)
increased the Cmax and area under the curve of rolapitant by 5.1 and 5.7 times, respectively. However, fatty
meal intake did not influence its absorption [3].

While cytochrome P450 (CYP) enzyme activation is the cause of the majority of observed drug-drug
interactions through another NK-1RA, the degree of interaction varies, necessitating dose changes for
concomitant drugs like dexamethasone [4]. The cytochrome P450 3A4 (CYP3A4) enzyme is metabolized by
rolapitant, although it does not inhibit or activate it. Rolapitant should not be taken with rifampicin, a
CYP3A4 inducer; however, it does have a minor inhibitory effect on cytochrome P450 2D6 (CYP2D6), breast
cancer resistance protein (BCRP), and P-glycoprotein (P-gp) [5].

The facts produced in this research support the interpretation of teratogenic effects like anatomical
malformations and abnormal skeletal changes affected by high doses of rolapitant in developed chick
embryos, which can be extrapolated to humans due to gaps in the literature regarding rolapitant’s
teratogenic potential. As it is metabolized by the liver and excreted through the kidneys by leaving a deep
impact on the various systems of the body and due to its high plasma concentration with a half-life of more
than 180 hours, the study was conducted to acquire some additional information about its adverse effects
over the various body systems. This study aimed to see if rolapitant, an antiemetic medicine, may cause
teratogenic effects in developing White Leghorn (Gallus domesticus) chicken eggs. To gain a comprehensive
understanding of embryological processes, researchers must examine and compare development in various
animals. The chick is one of the best animals for embryological laboratory research. For various reasons, it is
preferred to research embryology in chicks or domestic hens (G. domesticus). Chick eggs are large, readily
available all year, easy to incubate, and regulate artificially. Furthermore, the process of chicken growth has
been well investigated. An examination of the embryology of various birds reveals that it is almost identical
in all of them, with just minor variations. Chicken embryology is quite similar to human embryology.
Without a larval stage, the development proceeds directly [6].

Materials And Methods

Study area

This study aims to see whether rolapitant’s antiemetic effect on chick embryo development induced
abnormal morphological and skeletal effects on 300 (out of 330 eggs) White Leghorn chicken eggs. The
research was accomplished in the Department of Anatomy at Santosh Medical College in Ghaziabad, Uttar
Pradesh. The eggs were provided by Metro Feeds, Indotech Agro Products, Faridabad, India.

Inclusion and exclusion criteria

The well-calcified eggs were included with an entire shell, an air cell with a broad end, and an egg’s air cell
free of blood clots. Thirty eggs were rejected due to cracked shells (n = 17), lack of an air cell at the broad end
(n = 8), and an air cell with a blood clot (n = 5).

Procedure

Natekar’s [7] standard approach was used to conduct the study. Candles were used to obliterate faulty eggs,
and a pencil was used to mark the precise location of the air cell. A custom-built wooden box with a compact
fluorescent light (CFL) connector and a dark interior was employed. There are spaces for chicken eggs on the
top. After being well cleansed with soap water, the eggs were kept in the incubator with their broad end
facing the chorioallantoic membrane. The incubator’s temperature and humidity were kept at 38°C and 85%-90%,
respectively, without the addition of CO2 (carbon dioxide) or O2 (oxygen). Twice a day, the eggs were
inverted. Eggs were taken from the incubator and lit with candles again on the fifth day of incubation to
determine the start of the embryogenesis process before being given the drug. Natekar’s approach [7] was
used by Singroha et al. (2012) [8], Thongphanich and Roongruangchai (2013) [9], Hussein (2014) [10], and
Mittal et al. (2015) [11].
Dose setting

The recommended dose of rolapitant for adults, as approved by the US FDA, is 180 mg via the oral route, i.e., 3 mg/kg of average body weight (60 kg). On the fifth day of incubation, the weight of a chick embryo was 0.13 grams [12]. Details of dose titration for experimental and control groups of chick embryos are as follows (Table 1).

| Groups | Experimental groups | Control groups |
|--------|---------------------|----------------|
|        | Dose (rolapitant)   | Sample size (n1) | Dose (NS)          | Sample size (n2) |
| A      | 0.00039 mg          | 30              | 0.039 ml/1.56 Units | 30               |
| B      | 0.0005 mg           | 30              | 0.05 ml/2 Units    | 30               |
| C      | 0.00075 mg          | 30              | 0.075 ml/3 Units   | 30               |
| D      | 0.001 mg            | 30              | 0.1 ml/4 Units     | 30               |
| E      | 0.00125 mg          | 30              | 0.125 ml/5 Units   | 30               |

TABLE 1: Dose preparation for chick embryos for the administration of rolapitant into the five experimental groups

N = 30 in each experimental (n1) and control groups (n2).

NS: Normal saline; mg: milligram; ml: milliliter; Unit: measured by tuberculin syringe.

Dose titration

Calculated dose of drug for chick embryo = 3 × 0.13/1000 = 0.00039 mg (on incubation day 5). The following method was adopted to prepare the doses. Rolapitant power contains 10 mg of drug dissolved in 10 ml of distilled water (called solution A). Step 1: 1 ml of solution A was taken in a test tube; 1 ml of solution A = 1 mg of the drug. Step 2: 1 ml of solution A diluted with 9 ml distilled water to get 10 ml of solution B. 1 ml of solution B now contains 0.1 mg of the drug. Step 3: 1 ml of solution B diluted with 9 ml of distilled water to get 10 ml of solution C. 1 ml of solution C now contains 0.01 mg of the drug. *0.039 ml of solution C contain 0.00039 mg of the drug (0.039 ml × 0.01 mg). Dose titration: To convert ml into unit of insulin syringe. *1 ml insulin syringe contains 0.025 ml (1/40). *0.039 ml (0.00039 mg) contains (0.039/0.025 ml) 1.56 units. The following seven units have different doses of drugs: 1 unit contains 0.00039 mg/1.56 unit = 0.00025 mg of the drug; 1.5 units contain 0.00039 mg of the drug; 2 units contain (0.00039 × 2/1.56) = 0.0005 mg of the drug; 3 units contain (0.00039 × 3/1.56) = 0.00075 mg of the drug; 4 units contain (0.00039 × 4/1.56) = 0.001 mg of the drug; 5 units contain (0.00039 × 5/1.56) = 0.00125 mg of the drug; 6 units contain (0.00039 × 6/1.56) = 0.0015 mg of the drug (lethal dose 50%). More than 50% of embryos were dead at this dose.

*A preliminary drug study was done to obtain a lethal dose of 50% (LD50). The dose of 0.0015 mg was found as LD50, at which more than 50% of chick embryos were found dead. *All concentrations of drug below LD50 was selected for the study, namely, 0.00039, 0.0005, 0.00075, 0.001, and 0.00125 mg except the dose of 0.00025 mg, at which no apparent abnormalities were detected. This is why we had chosen the above-selected doses in the present study.

Method for drug administration, collection, and preservation of chick embryos

The eggs were categorized into five experimental groups, designated as A, B, C, D, and E. Each group contained 30 eggs, and five control groups, a, b, c, d, and e, each containing 30 eggs. As seen in Table 1, various doses were administered. The eggs were shackled three to four times between two hands. The fluid was administered into the air sac with the help of an insulin syringe. The wide end of the eggs was cleansed with a sterile gauze pad saturated in 70% isopropyl alcohol solution before being placed in the incubator. The outline of the air shell was drawn with a pencil at the peripheral margin, set by keeping eggs against the light coming from a hole made in a specially formed wooden box supplied with an illuminator inside. With a lancet, a hole was punched through the center of the outer surface of the egg’s air shell. The drill point was utilized with caution because of the possibility of injuring the shell membranes inside. The drill point was used to insert the tuberculin syringe needle into the shell in a parallel fashion. During the intervals between administrations, the needle of the syringe was wiped with a sterile 70% isopropyl alcohol wipe (Figure 1).
Following injection, the opening in the shell was immediately sealed with candle-melted wax. Eggs that had been sealed after injection were reintroduced to the incubator at 38°C and 85%-90% humidity, where they were tilted twice a day at 38°C and 85%-90% humidity. After that, the eggs were alternately candled with a candle. A rotation of the eggs occurred twice a day. On the 20th day of incubation, the eggs were cracked using a knife to extract embryos for analysis. The number of alive and dead embryos was determined. An electronic weighing machine was used to assess the weight of chick embryos, and digital Vernier calipers were used to measure their crown-rump (CR) length (a distance between the tip of the beak and the end of the coccyx bone). Identification of morphological aberrations was performed using a necked eye and magnifying lens as well as Vernier calipers. Before the start of the investigation, 15 fertilized White Leghorn chicken eggs were established in an incubator without using normal saline or distilled water, or any medicine. On the 20th day of incubation, the eggs were lost; however, chick embryos were retrieved. Their weight and CR length were determined using electronic scales and digital Vernier calipers, respectively. Without providing any solution to the eggs, we determined the normal minimum weight of the embryos to be 32.28 g, the maximum weight to be 39.42 g, the minimum CR length to be 9.93 cm, and the maximum CR length to be 11.35 cm. Chick embryos' mean normal weight and CR length were 35.75 ± 2.15 g and 10.57 ± 0.45 cm, respectively. We used these data to compare the outcomes of the results between the control and experimental groups.

Dissection of chick embryos and staining of the skeleton

To identify skeletal defects in chick embryos, the ventral wall of the trunk was dissected, and all internal organs were removed. Chick embryos that have been eviscerated are preserved in a 10% formaldehyde solution. The eviscerated chick embryos were cleaned with tap water and processed according to McLeod’s protocol for double staining cartilage and bone with slight modifications. The embryos were fixed in 100% ethyl alcohol for seven days. Following fixation, embryos were stained for four days in a solution containing (a) 1 volume 0.1% Alizarin Red S in absolute ethyl alcohol, (b) 1 volume glacial acetic acid, and (c) 1 volume absolute ethyl alcohol. A 100-ml solution was used in a separate jar for each skeleton to avoid body parts overlapping to guarantee enough staining and consistency. Following staining, the embryos were rinsed with tap water and incubated for 48 hours in a 2% potassium hydroxide solution. To prevent mold proliferation, macerated pigmented embryos were passed through various percentages of glycerine (20%, 40%, 60%, and 80%) and then kept in pure glycerin containing some thymol crystals. For visualization reasons, photographs were taken in the department’s photographic laboratory.

Statistical analysis

Statistical Package for the Social Sciences (SPSS) software v15.0 (SPSS Inc., Chicago, IL) was used for statistical analysis. For dichotomous variables, proportions were employed, whereas for continuous variables, mean and standard deviation were used. Where applicable, the chi-squared test was used to find the proportional connection. The chi-squared trend test was also used to see if there was a link between rising rolapitant doses and other developmental problems. If necessary, continuous variables were compared using the paired/unpaired t-test. A p-value of less than 0.05 was defined as statistically significant.

Results

In all doses, the control groups had a higher average weight than the experimental groups and were
statistically significant in groups D and E (p-value < 0.05). Similarly, short CR length (CRL) was noted more in a number of chick embryos of experimental groups as compared to control groups and was found statistically significant in groups D and E (p-value < 0.05). The mean weight in the control groups was substantially higher than the mean weight in the experimental groups, except for groups A and B. Similarly, the mean CRL in the control groups was substantially longer than the mean CRL in the experimental groups, except for groups A and B (P-value < 0.05). There were more deaths in the experimental groups than in the controls. The deadly effect of rolapitant demonstrated a subsequent considerable rise in lethality with the dose increase. While analyzing the lethal impact of the drug on a number of chick embryos, the majority of the death occurred in group D (p = 0.0377) and E (p = 0.0073), which showed a statistically significant difference. The total number of dead chick embryos in the control and experimental groups was noted as eight and 30, respectively (Figure 2 and Tables 2–4).

FIGURE 2: Lethal impact of rolapitant on developing chick embryos

(A) Growth-retarded dead chick embryo. (B) Number of alive and dead chick embryos in experimental and control groups induced by rolapitant.
| Name of the group | Number of chicken born with normal weight | Number of chicken born with less than normal weight | Number of chicken born with more than normal weight | Number of chicken born with normal CRL | Number of chicken born with less than normal CRL | Number of chicken born with more than normal CRL |
|-------------------|-----------------------------------------|-----------------------------------------------|-----------------------------------------------|---------------------------------------|-----------------------------------------------|-----------------------------------------------|
| a                 | 28                                      | 1                                             | 1                                             | 28                                    | 1                                             | 1                                             |
| A                 | 26                                      | 3                                             | 1                                             | 27                                    | 2                                             | 1                                             |
| b                 | 28                                      | 1                                             | 1                                             | 27                                    | 2                                             | 1                                             |
| B                 | 26                                      | 3                                             | 1                                             | 25                                    | 4                                             | 1                                             |
| c                 | 26                                      | 2                                             | 2                                             | 26                                    | 3                                             | 1                                             |
| C                 | 23                                      | 6                                             | 1                                             | 20                                    | 8                                             | 2                                             |
| d                 | 26                                      | 3                                             | 1                                             | 24                                    | 5                                             | 1                                             |
| D                 | 20                                      | 10                                            | 0                                             | 18                                    | 12                                            | 0                                             |
| e                 | 27                                      | 3                                             | 0                                             | 25                                    | 4                                             | 1                                             |
| E                 | 15                                      | 15                                            | 0                                             | 14                                    | 16                                            | 0                                             |

**TABLE 2: Number of chick embryos with weight and CRL due to the effects of rolapitant**

N: 30 eggs in each group; a, b, c, d, and e: control groups; A, B, C, D, and E: experimental groups; CRL: crown-rump length.

| Groups | Weight | P-value | CR Length | P-value |
|--------|--------|---------|-----------|---------|
|        | Control Mean ± SD | Experiment Mean ± SD | t | p |
|        | Control Mean ± SD | Experiment Mean ± SD | t | p |
| A      | 35.26 ± 2.32 | 34.92 ± 2.539 | 0.53 | 0.5982 |
| B      | 34.93 ± 2.066 | 33.78 ± 2.257 | 2.059 | 0.0439* |
| C      | 34.26 ± 1.948 | 32.8 ± 2.772 | 2.365 | 0.0214* |
| D      | 33.5045 ± 2.098 | 31.98 ± 2.168 | 2.849 | 0.0061* |
| E      | 34.58 ± 1.849 | 31.93 ± 2.728 | 4.335 | <0.0001* |

**TABLE 3: Mean, SD, t, and p-values of weight and crown-rump length in experimental and control groups**

A, B, C, D, and E: Compared groups; t: t-test; p: significant value; SD: standard deviation.

* indicates highly significant values.
| Name of the groups with doses | Number of fertile eggs used | Number of dead embryos | Number of live embryos | Percentile lethality (%) | Chi-square | P-value |
|-------------------------------|-----------------------------|------------------------|------------------------|-------------------------|------------|---------|
| a                             | 30                          | 0                      | 30                     | 0                       | 2.069      | 0.1503  |
| A                             | 30                          | 2                      | 28                     | 6.6                     | 1.071      | 0.3006  |
| B                             | 30                          | 3                      | 27                     | 10                      | 1.456      | 0.2276  |
| C                             | 30                          | 2                      | 28                     | 6.6                     | 4.32       | 0.0377* |
| D                             | 30                          | 8                      | 22                     | 26.6                    | 7.2        | 0.0073* |
| E                             | 30                          | 12                     | 18                     | 40                      |            |         |

**TABLE 4: Lethal impact induced by rolapitant on developing chick embryo**

Number of dead and alive chick embryos in both experimental (A, B, C, D, and E) and control groups (a, b, c, d, and e) with chi-square and p-values.

No morphological abnormalities were seen in either the control or experimental groups A and B. The small beak, scanty feathers, hematoma, and yolk sac retraction failure were detected in experimental groups C, D, and E. Prevalence was directly proportionate to a higher dose of the drug. However, most of the morphological abnormalities were determined and found to be significant only in the experimental group E. When the skeleton abnormalities were analyzed, a significant rise in the number of various chick embryos of experimental groups induced by rolapitant was detected. Most of the skeletal anomalies such as poor ossification, bent or displacement, disoriented, thinning, fusion, undeveloped, or absence of the bones of axial and appendicular skeletons were observed after staining of the skeletal. The Alizarin Red with other substitute chemicals was used to stain the bones. Full absorption of staining by bones was noted as complete and normal ossification, those by which staining was absorbed less or partly were demonstrated as poor ossification, and those by which staining was not absorbed were declared as absent (Table 5 and Figures 3-8).
TABLE 5: Number of chick embryos with morphological malformation at different doses in experimental and control groups

N = 30 in each group; a, b, c, d, and e: control groups; A, B, C, D, and E: experiment groups.

FIGURE 3: Morphological abnormalities in developing chick embryos induced by rolapitant

(A) Dead chick embryo with short beak (yellow arrow), (B) scanty feathers (yellow arrow), (C) hematoma (black circle) on the left lateral thoracic wall of chick embryo with scanty feathers, and (D) failure of retraction of the yolk sac (arrow).
**FIGURE 5: Abnormal skeleton of a chick embryo**

(A) Poor ossification of mandible and maxilla, (B) poor ossification of skull, (C) cervical rib, (D) poor ossification of left clavicle, (E) poor ossification of radius and ulna with thinning, (F) absence of scapula and ribs (left sided), (G) poor ossification and thinning of right pelvis, (H) poor ossification of right tibia, and (I) poor ossification of right fibula.
FIGURE 6: Abnormal skeleton of a chick embryo

(A) Poor ossification of skull, (B) short mandible with poor ossification and thinning, (C) poor ossification of cervical vertebrae, (D) absence of right upper limb bones, (E) poor ossification of thoracic vertebrae, (F) poor ossification of ribs and scapula, (G) poor ossification of right femur (short), (H) absence of tail, (I) poor ossification of left pelvis, (J) short fibula with fused metatarsals and phalanges, and (K) poor ossification left humerus and absence of left radius, ulna, metacarpals, and phalanges.
FIGURE 7: Abnormal skeleton of a chick embryo

(A) Undeveloped sternum, (B) scoliosis, (C) poor ossification of right radius and ulna, (D) poor ossification of right metacarpals and phalanges, and (E) poor ossification of left pelvis.
In addition to the observation of skeletal anomalies as demonstrated in Figures 5-8, retarded or poor ossification of skull bones was seen in all groups except control groups “a” and “b.” Significant changes were observed in the experimental group E only and showed the retarded ossification in 30% and short mandible in 2%. However, the experimental groups showed more skeletal abnormalities in skull bones than the control groups. Skeletal abnormalities in the spinal column, with the exception of group A, and all others exhibited skeletal anomalies such as inadequate ossification or fusion, scoliosis, lordosis, kyphosis, and kinky or absent tail, while cervical rib was detected in group E only. However, it was more prevalent in the experimental group and directly proportionate to high doses of the drug. Rolapitant-induced abnormalities in the ribs such as poor ossification, absence, and synostosis were noted. The anomalies in the sternum such as poor ossification, displaced, and dumbbell shaped were detected. In the upper limb skeleton of chick embryos of the control and experiment groups, no abnormal changes were found in the control groups. While the experimental groups showed significant abnormalities like poor ossification of phalanges, metacarpals, radius, ulna, and carpal bones with thinning of radius, ulna, carpals, and metacarpals, abnormal alterations in the lower limbs such as inadequate ossification, shortening, bending or displacement, and fusion of the foot bones were noted (Tables 6-11).
### TABLE 6: Skeletal abnormalities in the skull due to the effects of rolapitant

N = 30 in each group. a, b, c, d, and e: control groups; A, B, C, D, and E: experiment groups.

| Groups | Retarded ossification (%) | Short maxilla | Short mandible | Congenital absence of cranium | Any other abnormality |
|---------|---------------------------|---------------|----------------|------------------------------|---------------------|
| a       | Nil                       | Nil           | Nil            | Nil                          | Nil                 |
| A       | 1 (3.3%)                  | Nil           | Nil            | Nil                          | Nil                 |
| b       | Nil                       | Nil           | Nil            | Nil                          | Nil                 |
| B       | 1 (3.3%)                  | Nil           | Nil            | Nil                          | Nil                 |
| c       | 2 (6.66%)                 | Nil           | Nil            | Nil                          | Nil                 |
| C       | 3 (10%)                   | Nil           | Nil            | Nil                          | Nil                 |
| d       | 1 (3.3%)                  | Nil           | Nil            | 1 (3.3%)                    | Nil                 |
| D       | 6 (20%)                   | Nil           | Nil            | Nil                          | Nil                 |
| e       | 1 (3.3%)                  | Nil           | Nil            | Nil                          | Nil                 |
| E       | 9 (30%)                   | Nil           | 2 (6.66%)      | Nil                          | Nil                 |

### TABLE 7: Skeletal abnormalities in the vertebral column due to the effects of rolapitant

N = 30 in each group. a, b, c, d, and e: control groups; A, B, C, D, and E: experiment groups.

| Groups | Not/poorly ossified (%) | Absent | Displaced or fused (%) | Scoliosis (%) | Lordosis (%) | Kyphosis (%) | Absent or kinky tail | Any other abnormality |
|---------|-------------------------|--------|------------------------|---------------|--------------|--------------|----------------------|---------------------|
| a       | Nil                     | Nil    | Nil                    | Nil           | Nil          | Nil          | Nil                  | Nil                 |
| A       | 1 (3.3%)                | Nil    | Nil                    | Nil           | Nil          | Nil          | Nil                  | Nil                 |
| b       | Nil                     | Nil    | Nil                    | Nil           | Nil          | Nil          | Nil                  | Nil                 |
| B       | 1 (3.3%)                | Nil    | 1 (3.3%)               | Nil           | Nil          | Nil          | Nil                  | Nil                 |
| c       | 1 (3.3%)                | Nil    | Nil                    | Nil           | Nil          | Nil          | Nil                  | Nil                 |
| C       | 4 (13.33%)              | Nil    | Nil                    | Nil           | 1 (3.3%)    | 1 (3.3%)    | Nil                  | Nil                 |
| d       | 3 (10%)                 | Nil    | Nil                    | Nil           | Nil          | Nil          | Nil                  | Nil                 |
| D       | 7 (23.33%)              | Nil    | Nil                    | Nil           | 1 (3.3%)    | 1 (3.3%)    | Nil                  | Nil                 |
| e       | 2 (6.66%)               | Nil    | 1 (3.3%)               | Nil           | 1 (3.3%)    | 1 (3.3%)    | Nil                  | Nil                 |
| E       | 8 (26.66%)              | Nil    | 1 (3.3%)               | 3 (10%)       | Nil          | 2 (6.66%)   | 1 (3.3%)             | Nil                 |
| Groups | Incomplete or poor ossification (% | Absent or displaced (%) | Synostosis (%) | Any other abnormality |
|--------|-----------------------------------|------------------------|----------------|----------------------|
| a      | Nil                               | Nil                    | Nil            | Nil                  |
| A      | 2 (6.66%)                         | 1 (3.33%)              | Nil            | Nil                  |
| b      | Nil                               | Nil                    | Nil            | Nil                  |
| B      | 3 (10%)                           | 1 (3.33%)              | Nil            | Nil                  |
| c      | 2 (6.66%)                         | 1 (3.33%)              | Nil            | Nil                  |
| C      | 5 (16.66%)                        | 1 (3.33%)              | Nil            | Nil                  |
| d      | 1 (3.33%)                         | 1 (3.33%)              | Nil            | Nil                  |
| D      | 8 (26.66%)                        | 2 (6.66%)              | Nil            | Nil                  |
| e      | 2 (6.66%)                         | 1 (3.33%)              | Nil            | Nil                  |
| E      | 12 (40%)                          | 3 (10%)                | 1 (3.33%)     | Nil                  |

**TABLE 8: Abnormalities in the rib due to the effects of rolapitant**

N = 30 in each group. a, b, c, d, and e: Control groups; A, B, C, D, and E: experiment groups.

| Groups | Poorly or not ossified (%) | Displaced (%) | Dumbbell shaped (%) | Synostosis (%) | Asternia (%) | Any other abnormality |
|--------|---------------------------|---------------|---------------------|----------------|--------------|----------------------|
| a      | Nil                       | Nil           | Nil                 | Nil            | Nil          | Nil                  |
| A      | 1 (3.33%)                 | Nil           | Nil                 | Nil            | Nil          | Nil                  |
| b      | Nil                       | Nil           | Nil                 | Nil            | Nil          | Nil                  |
| B      | 1 (3.33%)                 | 1 (3.33%)     | Nil                 | Nil            | Nil          | Nil                  |
| c      | 2 (6.66%)                 | Nil           | Nil                 | Nil            | Nil          | Nil                  |
| C      | 5 (16.66%)                | 1 (3.33%)     | Nil                 | Nil            | Nil          | Nil                  |
| d      | 1 (3.33%)                 | Nil           | Nil                 | Nil            | Nil          | Nil                  |
| D      | 7 (23.33%)                | 1 (3.33%)     | 1 (3.33%)           | Nil            | Nil          | Nil                  |
| e      | 1 (3.33%)                 | Nil           | Nil                 | Nil            | Nil          | Nil                  |
| E      | 11 (36.66%)               | 2 (6.66%)     | 2 (6.66%)           | Nil            | Nil          | Nil                  |

**TABLE 9: Various abnormalities in the sternum in experimental and control groups with the number of chick embryos**

N = 30 in each group. a, b, c, d, and e: Control groups; A, B, C, D, and E: experiment groups.
| Name of the bones | Control group | Experimental group |
|-------------------|---------------|---------------------|
|                   | Poorly ossified or not ossified (%) | Poorly ossified or not ossified (%) | Poorly ossified or not ossified (%) |
|                   | a    b    c    d    e | a    b    c    d    e | a    b    c    d    e |
| Clavicle          | No   No   No   No   1 | No   No   No   No   No | No   No   No   No   No |
| Scapula           | No   No   No   No   1 | No   No   No   No   No | No   No   No   No   No |
| Humerus           | No   No   1    1    1 | No   No   No   No   No | No   No   No   No   No |
| Radius            | No   No   1    1    2 | No   No   No   No   No | No   No   No   No   No |
| Ulna              | No   No   No   No   1 | No   No   No   No   No | No   No   No   No   No |
| Carpals           | No   No   No   No   1 | No   No   No   No   No | No   No   No   No   No |
| Metacarpals       | No   1   1    1    2 | No   No   No   No   No | No   No   No   No   No |
| Phalanges         | No   1   1    1    2 | No   No   No   No   No | No   No   No   No   No |

**TABLE 10: Abnormal changes in the skeleton of upper limb exposed to rolapitant**

N = 30 in each group. a, b, c, d, and e: Control groups; A, B, C, D, and E: experiment groups.
N = 30 in each group. a, b, c, d, and e: Control groups; A, B, C, D, and E: experiment groups.

| Name of the bones | Control group | Experimental group |
|-------------------|---------------|-------------------|
| Name of the bones | Poorly ossified or not ossified (%) | Shortened | Bent or displacement | Any other change |
| Pelvis | a | b | c | d | e | a | b | c | d | e | a | b | c | d | e | a | b | c | d | e | a | b | c | d | e | a | b | c | d | e |
| Femur | No | 1 | 1 | 1 | 1 | No | No | No | No | No | No | No | No | No | No | 1 | No | No | No | No | No | No | No | No | No | No |
| Tibia | No | 1 | No | No | 1 | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No |
| Fibula | No | No | No | 1 | No | No | No | No | 1 | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No |
| Tarsals | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No |
| Metatarsals | 1 | No | 1 | 1 | 2 | No | No | No | 1 | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No |
| Toes | 1 | No | 1 | 1 | 2 | No | No | No | 1 | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No |

| Name of the bones | Poorly ossified or not ossified (%) | Shortened | Bent or displacement | Any other change |
|-------------------|----------------------------------|-----------|---------------------|-----------------|
| Pelvis | A | B | C | D | E | A | B | C | D | E | A | B | C | D | E | A | B | C | D | E | A | B | C | D | E | A | B | C | D | E | A | B | C | D | E |
| Femur | 2 | 2 | 3 | 5 | 10 | No | 2 | No | 1 | 3 | No | No | 1 | 2 | 4 | No | Thin | Thin | Thin | Thin |
| Tibia | No | 2 | No | 2 | 6 | 8 | No | No | No | 1 | 4 | No | 1 | 1 | 2 | 4 | No | No | No | No | No |
| Fibula | 2 | 1 | 4 | 4 | 9 | No | No | No | No | 2 | No | No | 1 | No | 2 | No | No | No | Thin |
| Tarsals | No | No | No | No | No | No | No | No | No | 2 | 1 | No | No | No | No | 3 | No | No | No | No |
| Metatarsals | 2 | 1 | 3 | 4 | 7 | No | No | 1 | 1 | No | No | 2 | No | 1 | 4 | No | No | Thin | Fused | No |
| Toes | 2 | 1 | 4 | 4 | 8 | No | No | 2 | 2 | 3 | 2 | 1 | 2 | 2 | 1 | 5 | No | No | No | Fused | No |

**TABLE 11: Abnormal changes in the skeleton of lower limb exposed to rolapitant**

N = 30 in each group. a, b, c, d, and e: Control groups; A, B, C, D, and E: experiment groups.

A detailed description of the fatal and unfavorable effects of various doses of rolapitant at higher doses was seen as statistically significant in the experimental groups when compared with control groups. Statistically, chick embryos with abnormal weight was found highly significant in group D (p-value = 0.0283) and group E (p-value = 0.0007), with abnormal CRL found as highly significant in group D (p-value = 0.0195) and group E (p-value = 0.00029), with abnormal skull bone found highly significant in only group E (p-value = 0.0056), with abnormal vertebral column found highly significant in only group E (p-value = 0.0377), with abnormal ribs found highly significant in group D (p-value = 0.001) and group E (p-value = 0.002), with abnormal sternum found highly significant in group D (p-value = 0.022) and group E (p-value = 0.001), with abnormal upper limb skeleton found highly significant in group D (p-value = 0.047) and group E (p-value = 0.009), and with abnormal lower limb skeleton found highly significant in group C (p-value = 0.009), group D (p-value = 0.028), and group E (p-value = 0.006). In contrast with the findings, it was evident that the greatest anomalies, particularly at higher doses of rolapitant, occurred in the experimental groups in comparison to control groups (Table 12).
When a teratogen has an effect on the tissues of developing chick embryos, it causes morphological or functional abnormalities. This is referred to as a ‘teratogenic mechanism.’ A teratogen or one of its metabolites may induce the initial event in teratogenesis, with the teratogen affecting (a) an organ primordium that would subsequently be malformed, (b) embryonic tissues other than the malformed organ primordium, or (c) maternal tissue or placenta [13]. This study aimed to see how rolapitant affected the growth of developing chick embryos.

Across all doses in the current investigation, the mean weight and CR length of embryos were substantially greater in the control group than in the experimental group. The experimental group experienced a higher rate of death than the control group. Additionally, it was found that rolapitant’s lethality increases with dose. When skeletal anomalies in the vertebral column are analyzed due to rolapitant’s effects, all groups reveal abnormalities except group A. However, it was noted that it was more widespread in the experimental group and became more prevalent with repeated rolapitant dosages. Thus, the experimental group had the most anomalies, particularly at higher rolapitant doses. As shown in a review of teratological studies, “several factors contribute to abnormal cellular or subcellular development including chromosomal aberration, genetic mutation, mitotic interference, altered nucleic acid integrity or function, a lack of precursors and substrates, altered energy sources, enzyme inhibition, fluid osmotic imbalance, and altered membrane properties” [14].

Morphogenesis and tissue interaction are thought to be the fundamental regulators of differentiation and morphogenesis because they can occur between a pair of tissues or more with dissimilar attributes (heterotypic) or among the cells with similar properties (homotypic). Several cytotoxic drugs reduce cell quantity and impede cell proliferation, which is a key factor in the development of most deformities and teratogenesis [15]. Inhibition of RNA production and depletion of mucopolysaccharides, hydroxyproline, and phospholipids in the palatal shelves are the successive steps of this process [16].

The antiproliferative properties of cyclophosphamide, hypervitaminosis, amniocentesis, and chlorpromazine have all been investigated. Physical or chemical stress induces necrosis in tissues that are susceptible to anomalies in a couple of hours or days, according to numerous teratological studies. Higher doses result in cell death and teratogenesis, but lesser levels damage cells more slowly and may not cause...
any problems [17-20].

Cytotoxic substances affect cells differently. This could be due to several factors. There are several fundamental distinctions, the most important of which is the intrinsic cell distinction, which determines if a cell will live or die. A significant amount of vacuolation was detected in cells treated with 6-aminonicotinamides in ectodermal cells, although not in mesodermal or endodermal derivatives [21]. Diffusion indicates the nutritional condition of cells, which determines their sensitivity. The cells that are the farthest away from a nutrient supply are the ones that suffer the most [22].

The prescribing information for rolapitant hydrochloride (tablet Varubi) has been authorized by the US FDA, and it contains instructions on how to take the drug safely and effectively. Varubi’s safety in emetogenic chemotherapy patients was investigated in four randomized clinical trials, including over 2800 patients. Varubi patients had greater adverse events in cycle 1 than the placebo patients. Major congenital impairments and miscarriages in clinically diagnosed pregnancies in the overall population of the United States were estimated. In the pregnant rats given during organogenesis, the potential toxicity of rolapitant hydrochloride to embryos and fetuses was studied. Rats treated with rolapitant showed signs of maternal toxicity in the first week, including a decrease in body weight gain and dietary intake. There were no teratogenic or embryo-fetal damaging findings in rabbits. During organogenesis and lactation, rats were given oral doses of 2.25, 9, or 22.5 mg/kg per day to see how rolapitant affected their development. When given at a daily dose of 22.5 mg/kg, the following side effects were observed: mortality/moribund state, decreased weight and dietary intake, entire litter loss, postponed parturition, shortened gestation length, and an increased number of unaccountable implantation sites (on a body surface area basis, approximately 1.5 times the approved intravenous human dose). Lower postnatal survival, lower body weights, and weight gain were all observed in the offspring, which could be linked to the reported maternal toxicity. In female pups, a maternal daily of 9 mg/kg rolapitant (about 0.5 times the maximum authorized intravenous human dose on a body surface area basis) resulted in memory loss and weight loss. There were fewer, mean implantation sites, corpora lutea, and viable embryos at 22.5 and 45 mg/kg/day (about 1.3 and 2.6 times the recommended intravenous human dose on a body surface area basis, respectively) compared to control [23].

Similarly, rolapitant decreased apomorphine-provoked retching as well as vomiting in ferrets in a dose-dependent manner, according to Duffy et al. [24]. Rolapitant suppressed acute and delayed period retching plus vomiting caused by the highly emetogenic chemotherapy agent cisplatin in ferrets at the same dose range. The NK1 antagonist aprepitant, on the other hand, is approved in humans for the management of CINV and postoperative nausea with vomiting (PONV) and is administered orally before and after chemotherapy [25]. Rolapitant appears to be a highly selective and competitive NK1 antagonist with good oral and CNS penetration, according to these results. Following their activation in humans, a number of NK1 antagonists have been found to have antiemetic effects [26].

Rojas et al. (2015) evaluated the mechanisms of action and the most recent clinical studies for rolapitant and netupitant/palonosetron (NEPA), two novel NK1 receptor antagonists used to treat chemotherapy-related nausea as well as vomiting. Throughout the delayed phase of all studies, patients who were given rolapitant had a considerably higher rate of full response than the patients who were given placebo. In addition, the study mentioned above looked into rolapitant’s safety and tolerability. The most common TRAEs were fatigue, constipation, headache, diarrhea, dyspepsia, hiccups, and neutropenia (treatment-related adverse effects) [27]. Rapoport et al. (2016) studied rolapitant’s efficacy and safety in avoiding nausea and vomiting caused by repeated rounds of weakly or highly emetogenic chemotherapy [28]. Rolapitant was shown to be widely tolerated above multiple MEC or HEC cycles, with minimal risk of treatment-emergent adverse effects (TEAEs) such as fatigue, constipation, headache, and weight loss. Schwartzberg et al. (2015) investigated the usage of rolapitant in cancer patients who had received moderately emetogenic chemotherapy or anthracycline and cyclophosphamide schedules. When used in conjunction with a 5-HT3 receptor antagonist and dexamethasone, rolapitant has been found to be well tolerated and to outperform active control in terms of reducing CINV for the entire five-day (0-120 h) at-risk period after the moderately emetogenic treatment followed by anthracycline and cyclophosphamide schedules after mildly emetogenic chemotherapy [29].

Small samples and the single-centric study was the limitation of the study. To our knowledge, no data on the rolapitant’s effects on pregnant women were available. It is recommended that an extended study and a more detailed and thorough analysis should be done to strengthen the reliability and generalizability of the current investigation’s findings. This research may aid in understanding the teratogenic effects of rolapitant in growing chick embryos. The study outcomes could help medics improve CINV by developing novel treatment alternatives.

**Limitations of the study**

In this work, we may have found information about teratogenic effects that are associated with massive doses of rolapitant administered to embryonic chicken, and these effects may be extended to humans. We have no data on the effects of rolapitant on pregnant women. Clinicians may find this study’s findings beneficial in their quest to discover more effective ways to treat nausea and vomiting associated with chemotherapy. However, despite these flaws, the study has a demerit due to its small sample size and one-
Conclusions

The current study established that the effects of rolapitant increased the mortality rate, growth retardation, poor ossification, morphological deformity, and altered spinal column curvature. When excessive amounts of rolapitant are used, the substance poses hazards and deleterious effects. As a result, rolapitant should be used with caution only when a strong therapeutic indication criterion has been satisfied. Moreover, the drug has to be carefully monitored with all the clinical parameters and investigational profiles as recommended by the cancer protocols. It also reiterated that drug usage in pregnant women should be after necessary studies and approvals from regulatory agencies.

Additional Information

Disclosures

Human subjects: All authors have confirmed that this study did not involve human participants or tissue.

Animal subjects: The present research was approved by Institutional Ethical Committee vide letter no. SU/2017/1226(19), dated 18/12/2017, and necessary animal ethical clearance was obtained and registered under 1066/GO/Re/S/CPCSEA-New Delhi, dated 21/07/2017. Issued protocol number SU/2017/1226(19), dated 18/12/2017. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Rapoport BL: Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting. Cancer Manag Res. 2017, 9:41-50. 10.2147/CMAR.597543
2. Wang J, Wang X, Zhang ZY, Arora S, Lu S, Kansra V: Pharmacokinetics of rolapitant in patients with mild to moderate hepatic impairment. J Clin Pharmacol. 2018, 58:886-93. 10.1002/jcph.1066
3. Ibrahim MA, Preuss CV: Antiepileptic Neurokinin-1 Receptor Blockers. StatPearls Publishing, Treasure Island, FL; 2021.
4. Rashad N, Abdel-Rahman O: Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther. 2017, 11:947-54. 10.2147/DDDT.S108872
5. Gupta A, Zhang Y, Unadkat JD, Mao Q: HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2004, 310:534-41. 10.1124/jpet.104.065542
6. Kottwani A: Use of chick embryo in screening for teratogenicity. Indian J Physiol Pharmacol. 1998, 42:189-204.
7. Natekar PE: Methotrexate induced gross malformations in chick embryos. J. Hum. Ecol. 2007, 21:225-226. 10.1080/09709274.2007.11905976
8. Singroha R, Srivastava SK, Chhikara P: Effect of gentamicin on kidneys in developing chicks. Eur J Anat. 2012, 16:119-126.
9. Thongphanich S, Roongruangchai J: The effects of Alphacypermethrin pesticide on the development of in Ovo Gallus domesticus, the 29th National Graduate Research Conference. Mae Fah Luang University. 2013.
10. Hussein M, Singh V, Gupta P, Yadav B, Singh AK: Developmental and biochemical effects of imidacloprid on developing chick embryos. J Anat Sciences. 2014, 12:12-17.
11. Mittal LB, Ashoka RK, Singh V, Tomar S, Mishra A: Adverse effects of antimarial drug - alpha/beta arther on growth of developing chick embryo. Int J Multidiscip Res. 2015, 2:407-410.
12. Singh V, Mittal LB, Ashoka RK: Effects of α/β arther—an antimarial drug on cerebral cortex in developing chick embryo - a histopathological and immunohistochemical study. J Anat Soc India. 2017, 66:97-104. 10.1016/j.jansi.2017.12.005
13. Wilson JG, Andfraser FC: General principles and etiology. Handbook of Teratology. Wilson JG, Andfraser FC (ed): Springer, New York, NY; 1977. 1:357-85.
14. Grobstein C: Inductive tissue interaction in development. Adv Cancer Res. 1956, 4:187-256. 10.1016/s0065-230x(08)60725-3
15. Garber BB, Moscona AA: Reconstruction of brain tissue from cell suspensions: II. specific enhancement of aggregation of embryonic cerebral cells by supernatant from homologous cell cultures. Developmental Biology. 1972, 27:235-245. 10.1016/0012-1606(72)90100-5
16. Shapira Y, Shoshan S: The effect of cortisone on collagen synthesis in the secondary palate of mice. Arch Oral Biol. 1972, 17:1699-703. 10.1016/0005-9569(72)90232-4
17. Stefanovich V, Gnanely A: Preliminary studies of the lipids of normal and cleft palates of the rat. J Dent Res. 1971, 50:1560. 10.1177/00220345710500055201
18. Singh S, Mathur MM, Singh G: Congenital anomalies in rat fetuses induced by amniocentesis. Indian J Med Res. 1974, 62:394-401.
19. Singh S, Padmanabhan R: Teratogenic effects of chlorpromazine hydrochloride in rat fetuses. Indian J Med Res. 1978, 67:500-9.
20. Scott WJ: Cell death and reduced proliferative rate. Handbook of Teratology. Wilson JG, Fraser FC (ed):
21. Neubert D, Merker HJ, Kohler E, Krowke R, Barrach HJ: Biochemical aspects of teratology. Adv Biosci. 1971, 6:575-622. 10.1016/S0065-0768(08)50171-5
22. Farage-Elawar M, Rowles TK: Toxicology of carbaryl and aldicarb on brain and limb cultures of chick embryos. J Appl Toxicol. 1992, 12:239-44. 10.1002/jat.2550120405
23. Tag archives: schering-plough. (2015). Accessed: December 5, 2018: https://newdrugapprovals.org/tag/schering-plough/
24. Duffy RA, Morgan C, Naylor R, Higgins GA, Varty GB, Lachowicz JE, Parker EM: Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets. Pharmacol Biochem Behav. 2012, 102:95-100. 10.1016/j.pbb.2012.03.021
25. Curran MP, Robinson DM: Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs. 2009, 69:1853-78. 10.2165/1112036800000000000000
26. Diemunsch P, Joshi GP, Brichant JF: Neurokinin-1 receptor antagonists in the prevention of postoperative nausea and vomiting. Br J Anaesth. 2009, 103:7-13. 10.1093/bja/aep125
27. Rojas C, Slusher BS: Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: rolapitant and NEPA (netupitant/palonosetron). Cancer Treat Rev. 2015, 41:904-13. 10.1016/j.ctrv.2015.09.005
28. Rapoport B, Schwartzberg L, Chasen M, Powers D, Arora S, Navari R, Schnadig I: Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. Eur J Cancer. 2016, 57:23-30. 10.1016/j.ejca.2015.12.023
29. Schwartzberg LS: Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomized, active-controlled, double-blind, phase 3 trial. Lancet. 2015, 16:1071-78. 10.1016/S1470-2245(15)00394-5